Biomea Fusion Inc is a biotechnology business based in the US. Biomea Fusion shares (BMEA) are listed on the NASDAQ and all prices are listed in US Dollars. Biomea Fusion employs 57 staff and has a market cap (total outstanding shares value) of 0.00.
How to buy shares in Biomea Fusion
- Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
- Open your brokerage account. Complete an application with your details.
- Confirm your payment details. Fund your account.
- Research the stock. Find the stock by name or ticker symbol – BMEA – and research it before deciding if it's a good investment for you.
- Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
- Check in on your investment. Optimize your portfolio by tracking your stock.
Our top pick for
Beginners

Our top pick for
Building a portfolio

Our top pick for
Advanced traders

Biomea Fusion stock price (NASDAQ: BMEA)
Use our graph to track the performance of BMEA stocks over time.Biomea Fusion shares at a glance
Latest market close | $11.15 |
---|---|
52-week range | $2.84 - $16.28 |
50-day moving average | $6.32 |
200-day moving average | $7.86 |
Wall St. target price | $19.50 |
PE ratio | N/A |
Dividend yield | $0 (0%) |
Earnings per share (TTM) | $-1.85 |
Buy Biomea Fusion shares from these brokerages
Compare special offers, low fees and a wide range of types of investments among top trading platforms.*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
Is it a good time to buy Biomea Fusion stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Biomea Fusion price performance over time
Historical closes compared with the close of $11.15 from 2022-07-01
1 week (2022-06-27) | -7.32% |
---|---|
1 month (2022-06-03) | 108.80% |
3 months (2022-04-05) | 142.92% |
6 months (2022-01-05) | 49.26% |
1 year (2021-07-02) | -26.64% |
---|---|
2 years (2020-07-01) | N/A |
3 years (2019-07-01) | N/A |
5 years (2017-07-01) | N/A |
Biomea Fusion financials
Gross profit TTM | $0 |
---|---|
Return on assets TTM | -27.8% |
Return on equity TTM | -47.19% |
Profit margin | 0% |
Book value | $5.65 |
Market capitalisation | $325.2 million |
TTM: trailing 12 months
Biomea Fusion share dividends
We're not expecting Biomea Fusion to pay a dividend over the next 12 months.
You may also wish to consider:
- BioNTech (BNTX.US) (1.33% forward annual dividend yield)
Biomea Fusion overview
Biomea Fusion, Inc. , a biopharmaceutical company, focuses on the discovery and development of irreversible small molecules to treat patients with genetically defined cancers and metabolic diseases. Its lead product candidate is BMF-219, an orally bioavailable, potent, and selective irreversible inhibitor of menin, a transcriptional regulator in oncogenic signaling in multiple cancers. The company was incorporated in 2017 and is headquartered in Redwood City, California. .
Biomea Fusion in the news
Biomea Fusion Selected for Two Oral Presentations at the European Association for the Study of Diabetes Annual Meeting Describing BMF-219’s Potential as a Novel, Oral, Long-Acting, Acute Treatment for Type 2 Diabetes
Biomea Fusion Announces First Patient Dosed in Multiple Myeloma Cohort of COVALENT-101 Trial
Frequently asked questions
What percentage of Biomea Fusion is owned by insiders or institutions?Currently 34.851% of Biomea Fusion shares are held by insiders and 64.314% by institutions. How many people work for Biomea Fusion?
Latest data suggests 57 work at Biomea Fusion. When does the fiscal year end for Biomea Fusion?
Biomea Fusion's fiscal year ends in December. Where is Biomea Fusion based?
Biomea Fusion's address is: 900 Middlefield Road, Redwood City, CA, United States, 94063 What is Biomea Fusion's ISIN number?
Biomea Fusion's international securities identification number is: US09077A1060
More guides on Finder
-
How to buy Citrine Global (CTGL) stock when it goes public
Everything we know about the Citrine Global IPO, plus information on how to buy in.
-
How to buy Genelux Corporation (GNLX) stock when it goes public
Everything we know about the Genelux Corporation IPO, plus information on how to buy in.
-
How to buy Magic Empire Global (MEGL) stock when it goes public
Everything we know about the Magic Empire Global IPO, plus information on how to buy in.
-
How to buy Intchains Group (ICG) stock when it goes public
Everything we know about the Intchains Group IPO, plus information on how to buy in.
-
How to buy Biostage (BSTG) stock when it goes public
Everything we know about the Biostage IPO, plus information on how to buy in.
-
How to buy Wang & Lee Group (WLGS) stock when it goes public
Everything we know about the Wang & Lee Group IPO, plus information on how to buy in.
-
How to buy OptMed (OMED) stock when it goes public
Everything we know about the OptMed IPO, plus information on how to buy in.
-
How to buy Lichen China (LICN) stock when it goes public
Everything we know about the Lichen China IPO, plus information on how to buy in.
-
How to buy LeeWay Services stock when it goes public
Everything we know about the LeeWay Services IPO, plus information on how to buy in.
-
How to buy Nano Labs (NA) stock when it goes public
Everything we know about the Nano Labs IPO, plus information on how to buy in.
Ask an Expert